Company Website: http://www.bmrn.com/
BioMarin Pharmaceutical Inc. (BMRN) Recent Headlines
The typical Facebook employee makes double what the typical household in Silicon Valley makes — even as the region's household earnings rose to an all-time high last year.
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors,.
Is Sangamo's Gene-Editing Approach a Bust?
Investors got more disappointing news regarding Sangamo Therapeutics' gene-editing approach this week.
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 7.) Array Biopharma Inc (NASDAQ: ARRY ) Down In The Dumps (Biotech ...
See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $1.26 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Reduced Rate of Decline Maintained in Children with CLN2 Disease, a Form of Batten Disease SAN RAFAEL, Calif. , Feb. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced ...
BioMarin Announces 14 Presentations at 15th Annual WORLDSymposium™ 2019
Presentations to Highlight Results from Studies for the Treatment of Three Forms of MPS and CLN2 Disease, a Form of Batten Disease SAN RAFAEL, Calif. , Feb. 4, 2019 /PRNewswire/ -- BioMarin Pharmaceutical ...
3 Gene Therapy Stocks With Huge Catalysts in 2019
Clinical trial readouts on the way will move these stocks before 2019's finished.
Biotech Conference Highlights Pipeline at BioMarin
At the recent JPMorgan Conference, biotech BioMarin Pharmaceutical (BMRN) offered a presentation that included important and new information regarding its R&D; pipeline for 2019, observes biotech specialist John McCamant, editor of The Medical Technology Stock Letter.
BioMarin Pharmaceutical Inc. (BMRN) Research Links
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Stock Message Board
